Rahmel, Tim
Kraft, Felix
Haberl, Helge
Achtzehn, Ute
Brandenburger, Timo
Neb, Holger
Jarczak, Dominik
Dietrich, Maximilian
Magunia, Harry
Zimmer, Frieda
Basten, Jale
Landgraf, Claudia
Koch, Thea
Zacharowski, Kai
Weigand, Markus A.
Rosenberger, Peter
Ullrich, Roman
Meybohm, Patrick
Nierhaus, Axel
Kindgen-Milles, Detlef
Timmesfeld, Nina
Adamzik, Michael
Clinical trials referenced in this document:
Documents that mention this clinical trial
Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study
https://doi.org/10.1186/s13054-022-04059-0
Funding for this research was provided by:
Universitätsklinikum der Ruhr-Universität Bochum
Article History
Received: 22 April 2022
Accepted: 13 June 2022
First Online: 7 July 2022
Declarations
:
: This study was initially reviewed and approved by the leading Ethics Committee of the Ruhr-University of Bochum (No. 21-7258), and subsequently by all local ethics committees of each participating centre. The requirement for an individual informed consent was waived due to the retrospective design and the deidentified nature of the data analysed.
: Not applicable.
: TR received a speaker’s honoraria from Biotest AG and grants from Deutsche Forschungsgemeinschaft (DFG) outside of the submitted work. FK has no conflict of interest to declare. HH has no conflict of interest to declare. UA has no conflict of interest to declare. TB has no conflict of interest to declare. HN has no conflict of interest to declare. DJ has no conflict of interest to declare. MD has no conflict of interest to declare. HM received a speaker’s honorarium from CSL Behring (Germany) outside the submitted work. FZ has no conflict of interest to declare. JB has no conflict of interest to declare. CL has no conflict of interest to declare. TK has no conflict of interest to declare. KZ has received honoraria for participation in advisory board meetings for Haemonetics and Vifor and received speaker fees from CSL Behring and GE Healthcare. He is the Principal Investigator of the EU-Horizon 2020 project ENVISION (Intelligent plug-and-play digital tool for real-time surveillance of COVID-19 patients and smart decision-making in Intensive Care Units) and Horizon Europe 2021 project COVend (Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19). MAW received speakers or advisory board honoraria from Biotest, SOBI, Pfizer, Gilead, MSD, Shionogi, Eumedica, BBraun. PR has no conflict of interest to declare. RU received speaker’s honoraria from Biotest AG outside of the submitted work and grants from Apeptico, Bayer and CCORE. He is a founding partner of CCORE, a medical device company. PM received speaker’s honoraria from Biotest AG outside of the submitted work. AN received speaker’s honoraria and travel reimbursement from Biotest AG, and speaker’s honoraria from ThermoFisher Scientific, CyoSorbents and Dräger Medical outside of the submitted work. DKM has received speaker’s honoraria from Biotest AG. NT has no conflict of interest to declare. MA received a speaker’s honoraria from Biotest AG and grants from the State of North Rhine Westphalia outside of the submitted work.